

# ForPatients

*by Roche*

## **A study to evaluate the safety, tolerability, processing by the body, mechanism of action, and effectiveness of glofitamab following obinutuzumab pretreatment in patients with B-cell non-Hodgkin lymphoma**

A Phase Ib, open-label, dose-escalation, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of subcutaneous glofitamab following obinutuzumab pretreatment in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

**Trial Status**  
Undefined

**Trial Runs In**  
0 Countries

**Trial Identifier**

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**

---

**Age**  
All

---

**Healthy Volunteers**

---